Mindray(SZ:300760)2026-04-01 09:59Summary of Mindray (300760.SZ) Earnings Review Company Overview - Company: Mindray (300760.SZ) - Industry: Medical Technology (Medtech) Device Manufacturing Key Financial Results - FY25 Revenue: Rmb33,282 million, a decrease of 9% year-over-year (yoy), in line with Goldman Sachs estimates (GSe) of Rmb33,442 million [1] - Net Profit: Rmb8,136 million, down 30% yoy, missing GSe of Rmb8,771 million [1] - Gross Profit Margin: Lower than expected due to VBP pricing erosion, higher R&D expenses, and exchange losses [1] Revenue Breakdown - Core Business Revenue Declines: - Patient Monitoring and Life Support (PMLS): -20% yoy - Medical Imaging: -18% yoy - In Vitro Diagnostics (IVD): -9% yoy [1] - Emerging Businesses: Recorded 39% yoy growth, including APT Medical, animal healthcare, and surgery [1] - Overseas Business: Grew by 7% yoy, now accounting for 53% of total revenue [2] - Domestic Business: Declined by 23% yoy due to: - Price reductions from Volume-Based Procurement (VBP) - Decreased usage of IVD reagents due to DRG/DIP reforms - Channel destocking of PMLS & Medical Imaging devices [2] Future Outlook - 2026 Revenue Expectations: Anticipated to turn positive, driven by Emerging Businesses growth [6] - Overseas Growth: Expected to outpace domestic growth, with all three core businesses projected to see some growth [6] - Impact of Middle East Crisis: Minimal effect on raw material supply; however, sales to the region have been significantly impacted, accounting for a single-digit percentage of overseas revenue [6] - R&D Investment: Expected to increase in 2026, with potential exchange rate losses due to RMB appreciation [6] Revised Estimates - 2026E Revenue: Rmb36,067 million, a decrease of 2.4% from previous estimates [7] - 2026E Net Profit: Rmb8,306 million, down 18.6% from prior estimates [7] - EPS: Expected to be Rmb6.85 for 2026, a reduction of 18.6% from previous forecasts [7] Investment Thesis - Market Position: Mindray is a leading medtech device manufacturer in China, with strong growth potential due to healthcare infrastructure development and domestic substitution [9] - Valuation: Currently trading below its 5-year average forward P/E, primarily due to policy risks [9] - Key Catalysts: Recovery in procurement activities, updates on medical device trade-in programs, and new product launches [9] Price Target and Risks - 12-Month Price Target: Rmb247, representing a 44.6% upside from the current price of Rmb170.77 [11] - Key Risks: - Further impacts from VBP on product pricing - Slower-than-expected penetration into top-tier hospitals in China - Challenges in entering North American and European markets - Patent-related lawsuit risks - Unexpected changes in trade policies [10] Conclusion - Mindray's performance in FY25 reflects significant challenges, particularly in domestic markets, but the company is positioned for potential recovery and growth through its emerging business segments and overseas expansion. The revised estimates indicate a cautious outlook, with a maintained Buy rating based on long-term growth potential and market leadership.